GLP1R and obesity disorder: The current obesity prevalence presents a significant paradox: despite notable therapeutic advances, including widespread use of GLP-1 receptor agonists (GLP-1RA) and SGLT2 inhibitors (SGLT2i) valued at $46.7 billion globally, the prevalence is expected to rise.